Login to Your Account



Targeting RORgamma, Phenex, J&J Ink $135M Collaboration

By Cormac Sheridan
Staff Writer

Wednesday, December 19, 2012
Phenex Pharmaceuticals AG and Johnson & Johnson subsidiary Janssen Biotech Inc., have thrown in their lot together in a combined effort to develop antagonists of retinoic acid-related orphan receptor gamma (RORγt) for inflammatory disease.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription